B. J. G. Pereira

B. J. G. Pereira is a physician-researcher associated with a central body of evidence on hepatitis C in end-stage renal disease, dialysis, and kidney transplantation. Across the cited studies, his work follows the patient through several linked thresholds: antibody positivity and survival, evaluation for transplantation, the comparative value of transplantation over continued dialysis, and the possibility that an infected organ may transmit hepatitis C virus to its recipient. His importance lies less in a single biographical episode than in the durable clinical questions his studies made unavoidable: how infection changes prognosis, when transplantation remains beneficial, and how transmission risk should be weighed against the scarcity of donor kidneys.

Identity and Field

B. J. G. Pereira appears in the medical literature as an author of major studies and reviews concerning hepatitis C virus infection in dialysis and renal transplantation. He is credited with a 1997 review on hepatitis C virus infection in dialysis and renal transplantation and with the New England Organ Bank Hepatitis C Study Group’s investigation into the effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The repeated appearance of his name in both clinical-outcome studies and transplantation-transmission studies places him at the intersection of nephrology, hepatology, transplantation medicine, and epidemiology.

The evidence associated with Pereira distinguishes several states that are often collapsed in simpler accounts. It refers to anti-HCV antibody positivity, active viremia assessed by nucleic acid testing, liver injury documented during pretransplant evaluation, and transmission demonstrated in donors and recipients. That distinction matters clinically: an antibody result identifies exposure or infection history, whereas active viremia and the severity of liver disease shape treatment, listing status, and transplant planning. Pereira’s work is therefore part of a broader shift from treating hepatitis C as a laboratory label to treating it as a time-dependent condition with consequences for survival, organ allocation, and graft function.

Survival and the Value of Transplantation

Pereira’s most consequential contribution in the cited evidence is the study of how hepatitis C modifies survival in end-stage renal disease. Across longitudinal dialysis cohorts, anti-HCV antibody positivity was independently associated with reduced survival. A meta-analysis of seven observational studies involving 11,589 patients receiving long-term dialysis estimated a relative risk of death of 1.34 for anti-HCV-positive patients, while liver-related mortality was markedly higher, with an unadjusted relative risk of 5.89. These findings frame infection as more than an incidental comorbidity: it becomes a force that changes the expected course of renal replacement therapy.

The same evidence complicates the apparent threat posed by long-term liver disease. In a large Australia and New Zealand cohort of 23,046 patients followed for ten years, anti-HCV-positive status remained associated with all-cause mortality, with a hazard ratio of 1.25, and hepatic failure was more common in the infected group, with an adjusted hazard ratio of 5.79. Yet hepatic failure remained infrequent, at 0.34 deaths per 100 patients per year, and the data suggested that many dialysis patients might die before developing the late complications of hepatitis C-related cirrhosis or hepatocellular carcinoma. Pereira’s field of inquiry thus required two scales at once: the elevated relative risk attributable to infection and the competing risks imposed by severe renal disease.

His survival analysis also supports transplantation as the preferred renal replacement therapy for infected patients who do not have advanced liver injury. The cited report found that anti-HCV-positive patients who received a kidney transplant had a relative risk of death of 0.31 during the seven-to-forty-eight-month posttransplant period compared with patients who remained on the waiting list. This comparison does not erase the hazards of hepatitis C or immunosuppression, but it changes the clinical decision. Continued dialysis is not a neutral fallback; for many infected patients, remaining on the waiting list carries a greater mortality burden than proceeding to transplantation.

Transplantation, Graft Outcomes, and Clinical Limits

Pereira’s work is also tied to the recognition that hepatitis C can affect the transplanted kidney as well as the patient’s liver and overall survival. Subsequent evidence summarized alongside his studies found inferior long-term survival among HCV-infected kidney transplant recipients, with the clearest differences often emerging more than ten years after transplantation. A meta-analysis of eight clinical trials involving 6,365 patients estimated a relative risk of mortality of 1.79 associated with HCV infection, partly because of increased liver-related death. The studies were largely retrospective and often classified infection through ELISA rather than more accurate nucleic acid testing, while pretransplant liver biopsies were frequently unavailable; those limitations temper the interpretation without removing the consistency of the signal.

Graft survival presents a parallel but distinct problem. In one comparison of 488 anti-HCV-positive recipients with 2,877 seronegative recipients, the adjusted relative risk for graft loss was 1.53. Registry data from Australia and New Zealand later found worse five-year graft survival in the anti-HCV-positive cohort, with an adjusted hazard ratio of 1.71 for graft failure. Graft loss was more often attributed to glomerulonephritis and chronic allograft nephropathy in the infected group. At the same time, not every study found an adverse effect, and some reported a nonsignificant decrease in graft loss among HCV-positive recipients. This mixed record reinforces the need to separate patient survival, graft survival, infection status, preexisting liver damage, and the causes of graft failure rather than treating them as one outcome.

The treatment implications are equally cautious. Screening before kidney transplantation should identify anti-HCV antibody and, where appropriate, active viremia through nucleic acid testing. Patients with active infection require assessment of liver disease, and liver biopsy remained the gold standard in the cited pretransplant framework despite the difficulties of performing it in dialysis patients with chronic uremia and impaired platelet function. Established or decompensated cirrhosis changes the transplant plan and may require referral for simultaneous liver-kidney transplantation. Interferon-based eradication efforts were therefore best concentrated before transplantation, because posttransplant interferon was associated with an increased risk of allograft rejection.

Transmission Through Organs

Pereira’s research also helped establish the biological and institutional stakes of using organs from hepatitis C virus-positive donors. Earlier transplantation studies demonstrated that hepatitis C virus can be transmitted through organ transplantation, and further work examined the prevalence of HCV RNA in antibody-positive cadaveric organ donors and their recipients. These studies transformed donor serology from a descriptive finding into an allocation problem: a positive donor may carry a risk of transmission, but refusing every such kidney contributes to the waste of organs in a system where demand greatly exceeds supply.

The transplantation of kidneys from HCV-positive donors remained controversial, with wide variation between centers and, in some countries, technical or legal prohibitions. The question was not simply whether transmission could occur. It was whether the transmission risk should be balanced against prolonged dialysis and the mortality associated with waiting. In the cited registry evidence, HCV-positive recipients who received HCV-positive kidneys waited 310 days less than the average waiting time at their center and 395 days less than comparable recipients who waited for HCV-negative kidneys. Receiving an HCV-positive kidney was independently associated with improved survival compared with remaining on the waiting list, with an adjusted hazard ratio of 0.76.

Long-term Spanish experience offered a more detailed comparison. Among 162 HCV-positive recipients of HCV-positive kidneys and 306 HCV-positive recipients of HCV-negative kidneys, followed for a mean of 74.5 months, patient survival did not differ, and liver-related deaths were scarce: three in the HCV-positive-donor group and two in the HCV-negative-donor group. Graft survival without censoring for death was lower in the HCV-positive-donor group, but the difference was attributed to older donors and recipients and to a higher frequency of pretransplant HCV RNA positivity. Donor HCV-positive serology was not an independent risk factor for death, graft loss, progression to advanced liver disease, or posttransplant glomerular disease. Decompensated chronic liver disease occurred in 10.3 percent versus 6.2 percent of recipients, a difference that was not statistically significant, while de novo posttransplant diabetes occurred more often in the first group but was not independently attributable to donor serology.

Infection Control and Institutional Significance

Although Pereira’s primary cited contributions concern transplantation and survival, the surrounding evidence places those questions within a larger system of infection control. Molecular virology studies demonstrated clusters of closely related HCV isolates among patients treated in the same hemodialysis units, supporting nosocomial transmission. A systematic review of twenty studies found no conclusively established route in any individual investigation, yet every study identified failures in infection-control procedures as the probable cause of new cases. In eighteen of the twenty studies, some or all newly infected patients did not share a dialysis machine with the source patient, suggesting that the internal machine circuit played, at most, a small role.

That conclusion shaped policy. Dedicated dialysis machines for HCV-infected patients were not recommended, and isolation in a separate ward was not considered an adequate substitute for strict infection-control procedures. Instead, prevention depended on handwashing before and after contact, gloves for patient care and potentially contaminated surfaces, disposal of single-use items, disinfection or patient dedication of nondisposable equipment, and cleaning of dialysis-station surfaces after every session. A new seroconversion required investigation of outside exposures, travel, transfusion, shared ward time, and possible breaches in hygiene, followed by an active search for additional cases, preferably with nucleic acid testing.

The institutional lesson complements Pereira’s transplantation work. Hepatitis C status is produced and acted upon through screening, molecular testing, biopsy, waiting-list surveillance, donor classification, and registry comparison. Patients with active viremia on a waiting list may be placed on hold and referred for hepatologic evaluation; those who have achieved sustained virologic response require at least annual nucleic acid testing, while viremic patients need repeated assessment of liver progression. In this chain, Pereira’s studies function as evidence for decisions that are simultaneously biological and administrative: whether a person remains eligible for kidney transplantation, whether an organ is accepted, and whether a shorter wait can justify an anticipated infection risk.

Legacy and Significance

Pereira’s legacy in the cited material is a carefully balanced argument rather than a one-sided endorsement of transplantation. Hepatitis C increases mortality among dialysis patients and can worsen long-term outcomes after transplantation, but transplantation still confers a survival advantage over remaining on dialysis when advanced liver injury is absent. Infection can be transmitted by an organ, yet an HCV-positive kidney may substantially shorten the wait and improve survival for an HCV-positive recipient. Antiviral therapy before transplantation may reduce later complications, but it can be prolonged, expensive, poorly tolerated, and unsuccessful; some patients remain viremic and should nevertheless be offered transplantation because their expected course may be better than continued dialysis.

That balance is especially important in an era of organ scarcity. Donated HCV-positive kidneys were reported to be 2.60 times more likely to be discarded than HCV-negative kidneys, even though many HCV-positive recipients might benefit from earlier transplantation. The evidence associated with Pereira therefore resists both reflexive exclusion and careless acceptance. It calls for precise classification of antibody and RNA status, staging of liver disease, attention to graft and patient outcomes, and allocation policies that recognize waiting time as a clinical risk. His work makes the central ethical arithmetic visible: the danger of transmission must be measured against the danger of delay, and the answer depends on the patient, the organ, the infection state, and the quality of the clinical system managing them.